Clinical trials: Non-hematologic Malignancies
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations
The purpose of this study is to establish a safe and systematic exercise assessment and prescription program for cancer survivors.
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer (Non-Small Cell), Liver Cancer, Adult
- Trial name
- NCT07751783
- Testing
- structured exercise training
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Non-Myeloid Malignancy
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who receiving Myelosuppressive Chemotherapy which…
- Trial name
- NCT04466137
- Testing
- YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Relapsed Adult AML
Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
Refractory/Relapsed (R/R) acute myeloid leukemia (AML) is associated with a dis-mal prognosis. In some subsets of AML such as AML driven by the t(8;21) translocation, leading to the RUNX1-RUNX1T1 (AML1-ETO) fusion transcript…
- Trial name
- CARLA-M19 (NCT06649227)
- Testing
- CAR-T cell therapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Lille
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies.
- Conditions
- Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05107856
- Testing
- PRT1419, Azacitidine, Venetoclax
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Prelude Therapeutics Incorporated
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
Acute Myeloid Leukemia Real World Treatment Patterns
Among patients with a diagnosis of AML who received non-intensive chemotherapy: Describe patient demographic and clinical characteristics Describe treatment patterns Describe effectiveness outcomes Evaluate tumor response
- Trial name
- NCT04230564
- Testing
- azacitidine, venetoclax, glasdegib
- Sponsor
- Pfizer
Multiple Myeloma
Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
Comparing intermediate-dose CTX (ID-CTX)and G-CSF with rhTPO or without for peripheral blood stem cell mobilization in patients with multiple myeloma, try to find out whether rhTPO combined to ID-CTX + G-CSF could improve the…
- Trial name
- NCT02572596
- Testing
- rhTPO, CTX, -CSF
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wang Guorong
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
- Trial name
- NCT01796470
- Testing
- Entospletinib, Idelalisib
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Cancer, Leukemia
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
This is a phase 2 study looking at efficacy and toxicity of oral sirolimus in combination with oral methotrexate in children with refractory/relapsed ALL or NHL.
- Conditions
- Cancer, Leukemia, Lymphoma
- Trial name
- NCT01162551
- Testing
- Sirolimus and Methotrexate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital of Philadelphia
Acute Myeloid Leukemia
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Mylotarg) for the potential treatment of acute myeloid leukemia (AML).
- Trial name
- NCT05189639
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- Pfizer
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
- Conditions
- B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma
- Trial name
- NCT07168486
- Testing
- CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia, Non-M3 Acute Myeloid Leukemia
Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML
This prospective cohort study aims to evaluate the prognostic significance of the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin level in newly diagnosed de novo non-M3 acute…
- Conditions
- Acute Myeloid Leukemia, Non-M3 Acute Myeloid Leukemia, De Novo Acute Myeloid Leukemia With Multilineage Dysplasia
- Trial name
- NCT07810829
- Volunteers
- 208 people
- Sponsor
- Assiut University
T-cell Lymphomas, NK-Cell Lymphomas
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory…
- Conditions
- T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
- Trial name
- NCT05010005
- Testing
- Ruxolitinib, Duvelisib
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004105
- Testing
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Where
- United States
- Sponsor
- NYU Langone Health
Multiple Myeloma, Relapse Multiple Myeloma
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Patients with relapsed/refractory symptomatic multiple myeloma who meet all inclusion criteria, will be randomized 1:1 to receive either standard of care chemotherapy (IKEMA or ICARIA) and dexamethasone until disease progression…
- Trial name
- FREEDOM (NCT06561854)
- Testing
- Dexamethasone
- Where
- France
- Volunteers
- 318 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.